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ABSTRACT
A high-performance liquid chromatography (HPLC) method was developed for the determination of 5-fluorouracil (5-FU) in 5-FU
injection and human serum. A Nova-park C18 column (3.9 × 150 mm, 4.6 μm) and mobile phase consisting of 5 mmol/L KH2PO4 (pH
6.0) – methanol (96:4, v/v) at a flow rate of 1.0 mL/min were used for separation. The detection wavelength was set at 254 nm. The human
serum was treated with AgNO3 (20%) and NaCl (20%). The method showed a good linear relationship in the range of 0.1 - 100 μg/mL (R2 =
0.9999) with limits of quantification (LOQ) at 0.10 μg/mL and 0.85 μg/mL (S/N = 10) in 5-FU injection and human serum, respectively. The
average recoveries of different concentrations in 5-FU injection and human serum were 95.79 - 105.1% and 90.2 - 108.8%, respectively.
The relative standard deviation (RSD) of precision was 0.4%, and those of stability and repeatability were less than 1.3% and 2.1% (n = 5)
in both samples, respectively. Impurities in the human serum did not interfere with the determination of 5-FU. The method is simple, rapid,
sensitive and can accurately determine 5-FU in 5-FU injection and human serum.
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INTRODUCTION
5-Fluorouracil (5-FU) is one of the anti-metabolite and
anti-tumor drugs that has been around and in use for decades.
It is most commonly used in the treatment of the cancers
of colon, breast, stomach and pancreas(1). 5-FU injection
is widely used and many products with the specification of
0.25 g/10 mL. Although 5-FU is an active medicine against
many cancers, it has some side effects(2-3). Some of the most
common and important side effects include soreness of the
mouth, difficulty swallowing, diarrhea, stomach pain, low
white blood counts, low platelet counts and anemia. 5-FU
has anti-tumor function only after it metabolizes into the
corresponding nucleotide in the body and there are metabolic
differences between different people. It had been proven that
if there were large amounts of 5-FU in the human serum
after injecting for certain hours, 5-FU would not metabolize
completely and would endanger health (2-3). Therefore, developing a simple, rapid, economical and accurate method for
the determination of 5-FU in human serum is necessary. So
far, gas chromatography-mass spectrometry (GC-MS)(4-5),
high performance liquid chromatography (HPLC)(6-12) and
high performance capillary electrophoresis (HPCE)(13) had
been used for the determination of 5-FU in human serum.
* Author for correspondence. Tel: 13504965827;
Fax: 87402449; E-mail: a330fo@hotmail.com

Methods which had been used for the determination of 5-FU
injection were HPLC(14), RP-HPLC(15) and HPCE(16). The
method developed in this study is simple, rapid, economical
and accurate, and it may be applied for the rapid determination of 5-FU in injection and human serum.

MATERIALS AND METHODS
I. Materials and Chemicals
5-FU was purchased from Sinopharm Chemical Reagents
Limited Company, China. Methanol was of chromatographic
grade. All other reagents were from standard sources. Ultrapure water was used. 5-FU injection was purchased from
Shanghai Xudong Haipu Pharmaceutical Co., Ltd. Human
serum was offered by the Central Hospital of LiaoYuan in
Jilin Province, China.
II. Preparation of Standard and Sample Solutions
5-FU standard (100 mg, accurately weighed) was placed
in a 50-mL volumetric flask. To this, 40 mL of water was
added and the mixture was sonicated for 30 s. The mixture
was made up to volume with water to obtain a final concentration of 2 mg/mL. This was used as the standard stock
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solution. The standard stock solution was diluted with water
to obtain a series of standard solutions (0.1 - 100 μg/mL). The
5-FU injection was diluted with water and filtered through a
0.22-μm membrane before analysis. AgNO3 (20%, 600 μL)
was added into a mixture containing human serum (1.0 mL)
and the standard stock solution of 5-FU (4 μL). The resulting
mixture was subjected to vortex for 3 min and placed to stand
for 5 min. NaCl (20%, 700 μL) was added and the mixture
was subjected to vortex for another 3 min. After centrifugation at 13,000 rpm for 12 min, the supernatant (0.5 mL) was
diluted with water to 1 mL in centrifuge tube and filtered
through a 0.22-μm membrane.
III. HPLC Conditions

during the test period (14 h). The RSDs were 1.3 and 1.8% in
5-FU injection and human serum, respectively.
V. Determination of Real Samples
5-FU injection and human serum were analyzed in triplicate. The concentration of 5-FU was calculated using the
regression equation of the calibration curve. The HPLC chromatograms of the real samples are shown in Figures 2 and 3.
Table 1. Linear range, regression equation and limit of quantification
of 5-FU calibration curve
Compound

Linear range
(μg/mL)

Regression
equation

Correlation
coefficient (r2)

5-FU

- 100

y = 74250 x +
7592.8

0.9999

A 600-Controller HPLC system (Waters, MA, USA)
with UV detector was used for the analysis. A Nova-park C18
column (3.9 × 150 mm, 4.6 μm) was used for separation. The
column temperature was maintained at 25°C. The standards
and samples were determined using a mobile phase consisting
of 5 mM KH2PO4 solution (pH = 6.0) and methanol (96 : 4) at
the flow rate of 1 mL/min. The injection volume was 20 μL.
The peak of 5-FU was detected at the wavelength of 254 nm.
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I. Calibration curve
5-FU was shown to exhibit a good linearity in the test
range. The standard stock solution was diluted to a series of
appropriate concentrations with water for the construction of
the calibration curve. At least ten concentrations of the solution were analyzed in triplicate, and the calibration curve was
constructed by plotting the peak areas versus the concentrations of 5-FU. The linearity results are shown in Table 1 and
the HPLC chromatogram of 5-FU is shown in Figure 2.
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Figure 1. HPLC chromatogram of 5-FU standard. (The concentration
of 5-FU is 20 μg/mL)
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The standard solution of 5-FU was analyzed continuously (n = 5), under the present chromatographic conditions.
The RSD calculated from the peak areas was 0.4%.
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5-FU injection and human serum spiked with 5-FU were
analyzed (n = 5). The average content in the 5-FU injection
was 24.45 mg/mL and the RSD was 0.2%. The average
content in the human serum spiked with 5-FU was 5.97 μg/mL
and the RSD was 2.1%.
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Sample solutions were injected and analyzed every
2 h. The results showed that 5-FU was stable in both samples

Figure 2. HPLC chromatogram of the 5-FU injection sample. (The
concentration of 5-FU is 20 μg/mL)
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Figure 3. HPLC chromatograms of the (A) human serum sample, and (B) human serum sample spiked with 5-FU standard at the level of 4 μg/mL.
* a and b are impurities.

Table 2. Relevant quantitative parameters of 5-FU in 5-FU injection
Compound

Content of sample
(μg/mL)

5-FU

16.24

Addition of standard
(μg/mL)

Determination
(μg/mL)

Average
recovery* (%)

RSD
(%)

8
16
24

23.22
32.30
42.30

95.79
100.2
105.1

1.7
0.9
2.3

LOQ
(μg/mL)

0.10

*Average of triplicate.

VI. Recovery by Standard Addition
The recovery of the method was evaluated by adding a
known amount of the standard stock solution of 5-FU separately into a certain amount of 5-FU injection (2 mL) and
human serum (1 mL). Three replicates were performed for
the test. The mixtures were prepared and analyzed using the
method mentioned above (MATERIALS AND METHODS II
and III). The contents, average recoveries and limits of quantification (LOQ) of 5-FU in the 5-FU injection and human
serum samples are shown in Tables 2 and 3, respectively.

DISCUSSION
The results of this study indicated that the HPLC run
time of 5-FU in human serum was within 2 min. The method
was shown to be simple, accurate and sensitive. The treatment of human serum with AgNO3 and NaCl was convenient,
and the impurities in human serum did not interfere with the

Table 3. Results of average recoveries and LOQ of 5-FU in human
serum
Addition
(μg/mL)

Determination
(μg/mL)

Average
recovery* (%)

RSD
(%)

6
12
24

5.97
10.82
26.12

99.50
90.17
108.8

0.7
0.3
1.2

LOQ
(μg/mL)

0.85

*Average of triplicate.

determination of 5-FU. The method could be applied for
the determination of 5-FU in injection and human serum. It
is applicable for the examination of 5-FU in the serum of
patients who have been injected 5-FU and for monitoring
concentration of the drug.
The methods of previous studies(4-6,8,10,12-14) have
disadvantages, including a longer analysis time (more than
2 min), the use of environmentally unfriendly solvents(6,8)
or the treatment of human serum using organic solvent and
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nitrogen(4,10). In comparison, the method developed in this
study required a shorter analysis time and relatively less
solvent consumption. It also provided a simple and convenient way of sample preparation.
The optimization of the analytical conditions used in
this study involved the evaluation of different mobile phases,
concentrations and pH values of the KH2PO4 solution. It was
found that these mobile phases resulted in longer analysis
times and poor peaks. Methanol and ethyl acetate were tested
as reagents for the treatment of human serum, but they were
found to be unsuitable due to the complexity of the process,
longer preparation times and interferences from some impurities. Therefore, the present conditions were chosen for this
method.

CONCLUSIONS
A simple, accurate, rapid and sensitive high-performance
liquid chromatographic (HPLC) method was developed for
the determination of 5-fluorouracil (5-FU) in 5-FU injection
and human serum.
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